Foldi J, et al. - Herein, pathologic complete response (pCR: ypT0/is ypN0) rate were analyzed among hormone receptor (HR) positive and negative cases of breast cancer treated with trastuzumab plus pertuzumab administered concurrently during both the taxane and anthracycline phases of paclitaxel and 5-fluorouracil/epirubicin/cyclophosphamide (FEC) neoadjuvant chemotherapy. pCR achievement was noted in 80% of HR-negative, HER2-positive breast cancers who were administered paclitaxel/FEC neoadjuvant chemotherapy concomitantly with pertuzumab and trastuzumab. The outcomes were similar to pCR rates seen in trials using HER2-targeted therapy during the taxane phase only of sequential taxane–anthracycline regimens.